Comparative In-Vitro Aerodynamic Characterization of Marketed Dry Powder Inhalers Using the Aerolizer Type of Device
Year: 2026
Type: preprint
Abstract: Formoterol fumarate (FF) and Budesonide combination in a dry powder inhaler dosage form is very commonly prescribed for the treatment of asthma, bronchospasm, chronic bronchitis, emphysema, and chronic obstructive pulmonary disease (COPD). The aerodynamic characteristics and delivered dose of different marketed products are generated during the patient's inhalation and reach the lungs, and give the necessary therapeutic action. To develop a dry powder inhalation product with the consistent delivery of aerodynamic characteristics until the product's shelf life is a challenge for many pharmaceutical companies. The in vitro evaluation is determined by using various techniques, such as Next Generation Impactor (NGI), Glass Twin impinger (GTI), and uniformity of delivered dose (UODD). This study fully compared aerodynamic properties in NGI, GTI, and UODD performance of different marketed products with the Aerolizer type of device. Hence, this technique is preferred by many pharmaceutical companies for the routine quality control testing for dry powder inhaler characterization. It is statutory in a multitude of Pharmacopoeias and adopted by the majority of regulatory bodies across the globe. The main purpose of this study was to evaluate statistically the in vitro evaluation generated using the latest NGI, GTI, and UODD operated at fixed flow rates of 60 L/min. Four marketed products, Foracort 200, Budetrol 200, Combihale FB, and Budamate 200, were chosen for the study and compared with the Aerolizer type of device. The aerodynamic character and delivered dose uniformity. We found a statistically significant difference in the above marketed products available on the Indian market.
Source: Research Square
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7236171114
